Quick Answer
BeOne Medicines Ltd. reported Net Income Loss of $286.93 million for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +144.5% in Net Income Loss from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$10.21 million | Q2 2015: -$5.64 million | Q3 2015: -$14.00 million | Q4 2015: -$27.25 million | Q1 2016: -$22.00 million | Q2 2016: -$24.12 million | Q3 2016: -$35.49 million | Q4 2016: -$37.60 million | Q1 2017: -$50.62 million | Q2 2017: -$60.55 million | Q3 2017: $117.39 million | Q4 2017: -$99.32 million | Q1 2018: -$104.60 million | Q2 2018: -$156.89 million | Q3 2018: -$144.03 million | Q4 2018: -$268.26 million | Q1 2019: -$167.64 million | Q2 2019: -$85.57 million | Q3 2019: -$307.36 million | Q4 2019: -$388.06 million | Q1 2020: -$363.74 million | Q2 2020: -$335.20 million | Q3 2020: -$425.22 million | Q4 2020: -$472.75 million | Q1 2021: $66.50 million | Q2 2021: -$480.34 million | Q3 2021: -$438.11 million | Q1 2022: -$435.20 million | Q2 2022: -$565.73 million | Q3 2022: -$557.56 million | Q1 2023: -$348.43 million | Q2 2023: -$381.14 million | Q3 2023: $215.41 million | Q1 2024: -$251.15 million | Q2 2024: -$120.41 million | Q3 2024: -$121.35 million | Q1 2025: $1.27 million | Q2 2025: $94.32 million | Q3 2025: $124.84 million.
- Over the full 12 years of available data (2014 to 2025), BeOne Medicines Ltd.'s Net Income Loss has grown by 1,669.8%.
- Historical annual values: Fiscal year 2025: $286.93 million | Fiscal year 2024: -$644.79 million | Fiscal year 2023: -$881.71 million | Fiscal year 2022: -$2.00 billion | Fiscal year 2021: -$1.46 billion | Fiscal year 2020: -$1.62 billion | Fiscal year 2019: -$948.63 million | Fiscal year 2018: -$673.77 million | Fiscal year 2017: -$93.11 million | Fiscal year 2016: -$119.22 million | Fiscal year 2015: -$57.10 million | Fiscal year 2014: -$18.28 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: